OR WAIT null SECS
Acquisition expected to be finalized in April
The Flamma Group, a company that produces and commercializes small molecule active pharmaceutical ingredients (APIs) for the life science industry, and a contract development and manufacturing organization (CDMO), will be acquiring a third API manufacturing site in Italy, come April 2022.
Earlier this year, Flamma reached an agreement with Teva Group for acquiring the Sicor Bulciago site located in Lecco, Italy, which is about 19 miles from Flamma’s HQ. It has more than 21,188 cubic feet of manufacturing capacity and has been previously inspected by the FDA, the Italian Ministry of Health (AIFA), the Brazilian Health Regulatory Agency (ANVISA), and has been accredited by the PDMA (Japan).
According to company executives, the deal strengthens and expands its manufacturing services as a fully integrated CDMO.
“We are extremely happy to bring the Bulciago site into the Flamma Group of companies," says Dr. Gianpaolo Negrisoli, Flamma's CEO. "This allows us to rapidly enhance our CMC offerings to our customers by providing further flexibility between sites. Having the ability to produce more generic APIs in Italy is in line with the European pharmaceutical strategy aiming to reshore by having a more robust and resilient supply chain in the pharmaceutical sector that is not totally dependent on Asia.”